Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 6
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.